These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 4613968)

  • 21. Dropped head associated with amantadine in Parkinson disease.
    Kataoka H; Ueno S
    Clin Neuropharmacol; 2011; 34(1):48-9. PubMed ID: 21242745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Controversial issues concerning the initial treatment of Parkinson's disease: L-Dopa or dopaminergic agonists?].
    Defer GL
    Rev Neurol (Paris); 1999 Jan; 155(1):43-5. PubMed ID: 10093847
    [No Abstract]   [Full Text] [Related]  

  • 24. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
    Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
    BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
    [No Abstract]   [Full Text] [Related]  

  • 26. [Amantadine for the treatment of levodopa dyskinesias in Parkinson's disease].
    Cersósimo MG; Scorticati MC; Micheli FE
    Medicina (B Aires); 2000; 60(3):321-5. PubMed ID: 11050808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Parkinson's disease.
    Eadie MJ
    Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
    Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
    Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Arguments in favor of the early treatment of Parkinson's disease with L-Dopa].
    Broussolle E
    Rev Neurol (Paris); 1999 Jan; 155(1):27-33. PubMed ID: 10093845
    [No Abstract]   [Full Text] [Related]  

  • 31. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dopa-therapy in the treatment of early stage Parkinson's disease].
    Broussolle E
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():91-7. PubMed ID: 10916042
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical inquiries. What is the best initial treatment of Parkinson's disease?
    Schreck J; Kelsberg G; Rich J; Ward R
    J Fam Pract; 2003 Nov; 52(11):897-9. PubMed ID: 14599387
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of Parkinson disease in patients with surgical problems].
    Sobolewski P
    Neurol Neurochir Pol; 2003; 37 Suppl 5():183-8. PubMed ID: 15098345
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Revision of the treatment strategy in Parkinson disease].
    Staal-Schreinemachers AL; Wesseling H; Lakke JP
    Ned Tijdschr Geneeskd; 1986 May; 130(20):914-8. PubMed ID: 3724865
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 37. Levodopa: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S23-37. PubMed ID: 12211137
    [No Abstract]   [Full Text] [Related]  

  • 38. Choice of treatment in Parkinson's disease.
    Stern GM; Lees AJ
    Practitioner; 1977 Oct; 219(1312):537-41. PubMed ID: 594012
    [No Abstract]   [Full Text] [Related]  

  • 39. Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease.
    Nomoto M; Nishikawa N; Nagai M; Yabe H; Nakatsuka A; Moritoyo H; Moritoyo T; Kubo M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S21-4. PubMed ID: 19131037
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.